baber/WOPTO huggingface dataset:
Patent FI-915590-A0 (FI)
Inventor: LIEN ERIC LOUIS
IPC: A23L35/00
Filed: 1991-11-27
Abstract: The invention disclosed herein comprises fat compositions primarily for use in nutritionally complete infant formulas in which the constituent palmitic acid oils and lauric acid oils are corandomized. The invention additionally includes such corandomized fat compositions with medium-chain triglycerides added, particularly for use in nutritional products for preterm or low birthweight infants. Such corandomization of two or more oils yields a mixture of triglycerides having a substantially different chemical makeup than that of the native oils themselves or than the native oils when randomized individually. Corandomization of the palmitic acid oils and the lauric acid oils affords an economical means of providing a very highly absorbed fat composition.
Patent FI-916107-A0 (FI)
Inventor: DE BOER HENDRIKUS BAUKE
IPC: A21D2/26
Filed: 1991-12-23
Abstract: The invention concerns with deep frozen, pre-proofed doughs that contain 0.5-10 wt% of a gelatin relating compound, optionally in combination with other dough improvers like ascorbic acid, vital gluten, xylanase, amylase or DATA-esters. In particular the combination with xylanase/amylase leads to unexpected results (s.v. and/or ovenspring of baked products made from the doughs). As gelatin relating compounds gelatin, hydrolysed gelatin, collagen hydrolysate and/or gelatin precursors can be used.
Patent FI-945198-A0 (FI)
Inventor: GOLE DILIP J
IPC: A23L27/00
Filed: 1994-11-04
Abstract: A fast dissolving, solid dosage form defined by a matrix containing gelatin, pectin and/or soy fiber protein and one or more amino acids having from about 2 to 12 carbon atoms.
Patent FI-950737-A0 (FI)
Inventor: LUTZ JUERG
IPC: A61P17/00
Filed: 1995-02-17
Abstract: A pharmaceutical formulation contg. at least one neutral or carboxylic acidic active ingredient with a dissociation constant below 10<-3>, mol. wt. below 500 and the following solubilities at room temp. (a) < 1% in water, (b) > 10% in 70% ethanol, (c) > 35% in CHCl3, (d) > 60% in pyridine comprises a transdermal therapeutic system contg. the active ingredient(s) in a galenic formulation which can take up sweat and from which the active ingredient(s) is/are constantly released over at least 24 hrs. by the action of the sweat water. Pref. the galenic formulation consists of 10-30 wt.% 5,6-benzo- alpha -pyron, 1-50 wt.% of a cremophor, 15-85 wt.% one or more polyalkylene glycols and opt. other emulsifiers, aids to consistency, aids to dissolution, solvents and/or higher 8-24C fatty alcohols.
Patent FI-951217-A0 (FI)
Inventor: ENGELHOLM TORBJOERN
IPC: A23N/
Filed: 1995-03-15
Abstract: A roller and a machine provided with a roller for peeling or shaping potatoes and similar products, the roller (8) comprising a cylindrical body (14) having a grinding surface (13) for contacting with the product (17) to be treated. To simplify the manufacture of the roller and enable the treatment of soft products, the grinding surface of the roller body has axially extending grooves (15) which form several treatment teeth (16) mutually spaced in the peripheral direction of the grinding surface.
Patent FI-970431-A0 (FI)
Inventor: MASTERS RONALD ANTHONY
IPC: C11D10/02
Filed: 1997-01-31
Abstract: Detergent compositions having good filming/streaking characteristics contain effective amounts of specific substantive materials to increase the hydrophilicity of the glass. Preferred formulas contain a amphoteric, including zwitterionic, and optionally, but preferably, anionic detergent surfactant at levels (e.g., from about 0.02 to about 15%); hydrophobic solvent; alkaline material, especially volatile alkaline materials comprising monoethanolamine or certain beta-amino-alkanol compounds; and salt of polycarboxylate, preferably polyacrylate, polymer at effective levels (e.g., from about 0.01% to about 10%, by weight of the composition).
Patent FI-972085-A0 (FI)
Inventor: BRIEADDY LAWRENCE EDWARD
IPC: A61K31/55
Filed: 1997-05-15
Abstract: PCT No. PCT/GB95/02700 Sec. 371 Date May 1, 1997 Sec. 102(e) Date May 1, 1997 PCT Filed Nov. 16, 1995 PCT Pub. No. WO96/16051 PCT Pub. Date May 30, 1996The invention is concerned with novel hypolipidemic compounds of formula (I), with processes and novel intermediates for their preparation, pharmaceutical compositions containing them and with their use in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions, and associated diseases such as atherosclerosis.
Patent IL-65733-A0 (IL)
Title: Process for the preparation of 3,3-dimethylglutaric acid
IPC: C07C55/02
Filed: 1982-05-11
Abstract: Process for the production of 3,3-dimethylglutaric acid from isophorone. In a first step the isophorone is converted with ozone into an ozone-addition product. The ozone-addition product is converted by hydrolysis into 3,3-dimethyl-5-oxohexanoic acid. The latter is converted into 3,3-dimethylglutaric acid by treatment with hydrogen peroxide.
Patent IL-74885-A0 (IL)
Title: Apparatus for separating agricultural produce from spurious matter
IPC: B07B13/10
Filed: 1985-04-11
Abstract: Apparatus for separating a mixture of agricultural products and stones including an impact element defining an impact surface, which element is operative to absorb appreciable kinetic energy from stones but to absorb a significanty lower amount of kinetic energy from agricultural products sought to be separated therefrom and apparatus for causing the mixture of agricultural products and stones to impinge on the impact surface.
Patent IL-79026-A0 (IL)
Title: 1-aryl-5-alkoximinoalkylaminopyrazoles,their preparation and their use as herbicides and plant growth regulators
IPC: A01N43/653
Filed: 1986-06-04
Abstract: 1-Aryl-5-alkoximinoalkylamino-pyrazoles of the formula   <IMAGE>   in which R represents cyano or nitro, or represents an optionally substituted heterocyclic radical, R1 represents hydrogen or alkyl, R2 represents hydrogen or alkyl, or represents optionally substituted aryl, R3 represents hydrogen, alkyl or alkenyl, or represents in each case optionally substituted aralkyl or aryl and Ar represents optionally substituted phenyl or pyridyl, are active as herbicides and plant growth regulants. Compounds of the formula   <IMAGE>  in which R'' has the same definition as R other than cyano, are also active and useful as intermediates as well.
Patent IL-96447-A0 (IL)
Title: Isoindolone derivatives and their preparation
IPC: A61P25/08
Filed: 1990-11-22
Abstract: New isoindolone derivatives of general formula (I) are   <IMAGE> (I) disclosed in which the radicals R represent hydrogen atoms or, together, form a bond, the symbol R' represents a hydrogen atom or a readily removable radical and the symbols R'' are identical and represent phenyl radicals which can be substituted with a halogen atom or a methyl radical at the ortho or meta position, in the (3aR, 7aR) form or in the form of a mixture of the (3aRS, 7aRS) forms, as well as their salts. These derivatives are useful as intermediates for the preparation of therapeutically active products.
Patent IL-98479-A0 (IL)
Title: Hexahydroazepine derivatives,their preparation and pharmaceutical compositions containing them
IPC: A61P25/18
Filed: 1991-06-13
Abstract: The invention relates to hexahydroazepine derivatives of formula: <IMAGE>  in which:   - A is a group chosen from the following: -CO-CH2-; -CH(OH)- CH2-: -CH2-CH2-; -CH=CH-; -C IDENTICAL C-;   - X represents hydrogen or a halogen;   - Y is a cyclohexyl group or, when X is hydrogen, a phenyl group; as well as their salts with inorganic or organic acids.
Patent AU-PP627498-A0 (AU)
Title: Novel peptides - i
IPC: C12N15/09
Filed: 1998-10-02
Abstract: The invention relates to an isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
Patent FI-20031017-A0 (FI)
Inventor: RAESAENEN JARI
IPC: B65D83/04
Filed: 2003-07-04
Abstract: The invention relates to an encapsulated blister package, which is especially a medicine package containing tablets ( 8 ) or pills. The package has the flat outer casing ( 1 ), most preferably made of cardboard, and the inner part ( 2 ) partly extractable from it, the inner part comprising the disc ( 7 ) formed as a blister package moutned rotatably onto the base ( 5 ). The base has an outlet opening or similar so that the tablet that has been brought to the opening by rotating the disc, can be pressed out of the disc and removed from the package through the opening.
Patent FI-20115857-A0 (FI)
Inventor: HUOVIALA RAUNO
IPC: H04W/
Filed: 2011-09-01
Abstract: The invention discloses a method, a system and computer program product for wireless network capacity management. The method comprises measuring network performance data, measuring reference data from at least one cell using at least two different wireless apparatuses, comparing the measured network performance data to the reference data, obtaining a cell specific performance analysis, applying the performance analysis to a portion of the network and simulating the effect of a capacity configuration upgrade.
Patent IL-100164-A0 (IL)
Title: Indan derivatives
IPC: A61P43/00
Filed: 1991-11-27
Abstract: 5-Substituted trans-1-piperazinoindan derivatives having general formula (I), wherein X is halogen, trifluoromethyl, alkyl, alkylthio, alkyloxy, hydroxy, alkylsulphonyl, alkyl- or dialkylamino, trifluoromethylthio or cyano; R is hydrogen, or alkyl, alkenyl, cycloalkyl, or cycloalkyl lower alkyl, optionally substituted with hydroxy, or R is a substituent (a), wherein n is an integer from 1 to 6; U is CH or N; Y is CH2, O, S or N-R<1>, R<1> being hydrogen or cycloalkyl, cycloalkylmethyl, alkyl or alkenyl optionally substituted with hydroxy or an optionally substituted phenyl group; W is O or S; Z is -(CH2)4-, (b), (c), where R<2> and R<3> are hydrogen or lower alkyl, -CH=CH-, -CH=CH-CH2-, optionally substituted 1,2-phenylene, 1,2-C6H4CH2- (to form a quinazolidinone or -thione ring system) or 1,2-C6H4CO- (to form a quinazolidindion or thioxoquinazolidinon ring system); and Ar is an optionally substituted phenyl, thiophene or furane ring; are selective, centrally acting 5-HT2 antagonists useful in the treatment of anxiety, depression, sleeping disorders, negative symptoms of schizophrenia and migraine.
Patent IL-122479-A0 (IL)
Title: Recombinant production of novel polyketides
IPC: C12N9/00
Filed: 1997-12-07
Abstract: Novel polyketides and novel methods of efficiently producing both new and known polyketides, using recombinant technology, are disclosed. In particular, a novel host-vector system is described which is used to produce polyketides synthases which in turn catalyze the production of a variety of polyketides.
Patent IL-123295-A0 (IL)
Title: Surface mounted fire and smoke seals
IPC: E06B5/16
Filed: 1996-10-09
Abstract: A surface mounted fire and smoke seal comprises a plastics (e.g. PVC) mounting strip which is turned through a right angle along one of its sides to define an upstanding wall 2. A first relatively flexible plastics strip 3 extends downwardly from the upper margin of the wall and is inclined towards the mounting strip at an angle approximating to 45{ to the wall. A second relatively flexible plastics strip 4 is attached to the floor 1 of the mounting strip and is inclined upwardly therefrom at an angle approximating to 45{ thereto. The two flexible strips 3,4 lie in substantially the same plane with a spacing between their free edges or with their free edges in contact. The strip can be fastened to the door jamb so that the door closes against the two flexible strips. A strip of intumescent material can be bonded to the floor of the mounting strip between the second flexible strip 4 and the side edge of the mounting strip remote from the wall 2.
Patent IL-124700-A0 (IL)
Title: Optical recording medium based on fabry-perot principle
IPC: C08L69/00
Filed: 1996-11-28
Abstract: The present invention is in the field of optical recording media, and is directed to an optical recording medium which comprises the following layers; a) a grooved transparent substrate (1), superposed by b) a recording layer comprising a partial mirror (2) of a material having a high complex index of refraction which is not within the pentagon defined by the vertices 7.15 - i3.93, 7.15 - i5.85, 8.96 - 6.28, 9.56 - i5.90, and 8.14 - i3.77 in the n,k plane, superposed by a buffer layer (3) comprising a nonliquid-crystalline high-molecular weight material and optionally a dye, superposed by a thick reflective layer (4), together forming a Fabry-Perot wherein the thickness (d) of the buffer layer within the grooves is set so that the reflection of the medium is in the high reflective state, optionally superposed by c) a protective coating (5). By virtue of the partial mirror, the buffer layer, and the thick reflective layer a Fabry-Perot etalon is created. Information can be written by deformation of one or more of the partial mirror, the buffer layer, the thick reflective layer, or the substrate. The deformation effects change or destroy the Fabry-Perot, and a decrease in reflection is created. As deformation effects are used for writing, a non-liquid crystalline high-molecular weight material can be used in the buffer layer. The tracking (keeping the writing laser within the grooves) can take place by employing the difference in reflected amplitude or phase of the partial mirror/substrate interface within and outside the groove.
Patent IL-135105-A0 (IL)
Title: The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IPC: C07D261/00
Filed: 1998-04-14
Abstract: This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF- alpha  converting enzyme (TACE, tumor necrosis factor- alpha  converting enzyme) of formula (B) wherein (B) is (1), (2), or (3); P and Q are (4) or (5), provided that when P is (4), Q is (5), and vice versa; T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R<1>; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; (6) is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteroatoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R<1>; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri-substituted with R<1>; R<1> is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, -(CH2)nZ, -OR<2>, -CN, -COR<2>, perfluoroalkyl of 1-4 carbon atoms, -CONR<2>R<3>, -S(O)xR<2>-OPO(OR<2>)OR<3>, -PO(OR<2>)R<3>, -OC(O)NR<2>R3, -COOR<2>, -CONR<2>R<3>, -SO3H, -NR<2>R<3>, -NR<2>COR<3>, -NR<2>COOR<3>, -SO2NR<2>R<3>, -NR<2>CONR<2>R<3>, -NR<2>C(=NR<3>)NR<2>R<3>, -SO2NHCOR<4>, -CONHSO2R<4>, -tetrazol-5-yl, -SO2NHCN, -SO2NHCONR<2>R<3>, or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R<2>; R<2> and R<3> are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R<4> is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R<5> is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n = 1-6; x = 0-2 or a pharmaceutically acceptable salt thereof.
Patent IL-141766-A0 (IL)
Title: 2-methyl-thieno-benzodiazepine formulation
IPC: C07D243/00
Filed: 1999-03-24
Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.
Patent IL-145894-A0 (IL)
Title: Use of heparin-binding antagonists in the inhibition of bradykinin release
IPC: C07K14/47
Filed: 2000-04-28
Abstract: The invention is related to a method for treating or preventing a disorder resulting from the release of bradykinin in said mammal, particularly a mammal which produces an HBP which binds to an HBP antagonist, e.g. a monoclonal antibody that binds to at least one epitope of human HBP, comprising administering to said mammal an HBP antagonist in an amount effective to decrease the release of bradykinin in a mammal. Furthermore, the invention is directed to methods and kits for determining if a mammal produces HBP that binds to an HBP antagonist, e.g., a monoclonal antibody that binds to at least one epitope of human HBP and a method for detecting an antagonist of HBP.
Patent IL-149045-A0 (IL)
Title: Diagnosis and therapy of cancer using sgp28-related molecules
IPC: G01N33/58
Filed: 2000-10-27
Abstract: The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.
Patent IL-156306-A0 (IL)
Title: Pyrimidineamines as angiogenesis modulators
IPC: A61K31/53
Filed: 2001-12-19
Abstract: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
Patent IL-165795-A0 (IL)
Title: Packaging comprising a container in the form of a cup
IPC: B65D77/20
Filed: 2004-12-16
Abstract: The packaging (10), especially for foodstuffs, has a tub (12) with an upper opening (16) surrounded by a flat rim (20). The opening is covered and sealed by a polymer film (14), secured to the rim by a peripheral weld (22). The sealing film carries a weakened line (24) for a circular section (18) to be pulled clear by a tab (26). The peripheral weld has a stronger hold than the resistance of the weakened film line.
Patent IL-185656-A0 (IL)
Title: Lossless encoding of information with guaranteed maximum bitrate
Filed: 2007-09-02
Abstract: A compact encoded representation of information values not exceeding a predefined size can be derived when a first encoding rule generating an encoded representation of the information values of variable length is compared to a second encoding rule generating an encoded representation of the information values of fixed length and when the encoding rule resulting in the encoded representation requiring the lower number of information units is chosen. Thus, the maximum bit rate can be guaranteed to be at least the maximum bit rate of the second encoding rule deriving the second encoded representation. Signaling the choice of the encoding rule by some rule information together with the encoded representation of the information values, the correct information values can later on be derived on a decoder side, using a decoding rule fitting the encoding rule used during the encoding.
Patent IL-190946-A0 (IL)
Title: Conditionally immortalized long-term stem cells and methods of making and using such cells
IPC: C12N5/0735
Filed: 2008-04-17
Abstract: Disclosed are methods for conditionally immortalizing stem cells, including adult and embryonic stem cells, the cells produced by such methods, therapeutic and laboratory or research methods of using such cells, and methods to identify compounds related to cell differentiation and development or to treat diseases, using such cells. A mouse model of acute myeloid leukemia (AML) and cells and methods related to such mouse model are also described.
Patent IL-192950-A0 (IL)
Title: Soluble il-17rcx4 and methods of using in inflammation
Filed: 2008-07-22
Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. IL-17RC is a common receptor for IL-17A and IL-17F. The present invention includes methods of using a soluble IL-17RC receptor, IL-17RCx4 for treating inflammation.
Patent IL-194572-A0 (IL)
Title: Clamping fixture including a chuck for releasably locating a workpiece pallet
Filed: 2008-10-06
Abstract: The fixture has a clamping member (5) including a feedthru bore so that correct locking and/or releasing of the clamping member are ensured. The feedthru bore of the clamping member is closed off at one end of the fixture. A locking pin (10) is provided with another feedthru bore for locking and/or releasing of the bore of another clamping member. Each feedthru bore is connectable by a connecting conduit to a compressed air source. A sensor is provided for sensing air flow in the connecting conduit.
Patent RO-128860-A0 (RO)
Title: System of flat polygonal solar panels modular built for being integrated into the facades
Inventor: VISA ION
IPC: F24S10/70
Filed: 2013-02-18
Abstract: The invention relates to a system of flat polygonal solar panels modular-built for being integrated into the facades for generating heat energy and/or electricity from solar energy while ensuring a high degree of esthetical and architectural harmonization with the facade configuration and functional efficiency. According to the invention, the system comprises some flat polygonal solar panels (PSM) modular-built for being integrated into the facades and is obtained by the functional compatible connection of thermal and/or photovoltaic panels (PSM) of triangular or multi-triangular shape with glass or absorbent surfaces colored in adequate colours meant for optimal usage of facade surface for generating heat energy and/or electricity while ensuring a high degree of esthetical and architectural harmonization with the facade configuration and functional efficiency, the panels being some single-piece units with distinct geometrical shape obtained by connecting a minimal number of congruent triangles of equilateral or isosceles right triangle type, the sides of the equilateral triangle and the catheti of the isosceles right triangle having the same size (a) which allows the esthetical and functional interconnection of the type of side (a) and hypotenuse on hypotenuse, single-piece units with the shape of a rhombus (two equilateral triangles), isosceles trapezium (three equilateral triangles), parallelogram (four equilateral triangles), regular hexagon (six equilateral triangles), square (two isosceles right triangles), rectangle (four isosceles right triangles), isosceles trapezium (four isosceles right triangles), hexagon (eight isosceles right triangles).